ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a buy rating to a strong-buy rating in a report published on Saturday.

A number of other analysts have also commented on the company. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. Guggenheim raised their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $81.86 on Friday. The stock has a fifty day moving average of $76.82 and a 200 day moving average of $81.01. ANI Pharmaceuticals has a 52 week low of $56.71 and a 52 week high of $99.50. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 20.72 and a beta of 0.46. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.97% and a net margin of 8.87%.The company had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same quarter last year, the firm posted $1.70 earnings per share. The firm’s revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts expect that ANI Pharmaceuticals will post 7.64 earnings per share for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 5,323 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $78.02, for a total transaction of $415,300.46. Following the completion of the transaction, the insider owned 84,840 shares of the company’s stock, valued at approximately $6,619,216.80. This trade represents a 5.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Ori Gutwerg sold 2,060 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total value of $157,590.00. Following the transaction, the senior vice president directly owned 84,782 shares of the company’s stock, valued at $6,485,823. This represents a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 27,860 shares of company stock valued at $2,111,581. Company insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently modified their holdings of ANIP. Arrowstreet Capital Limited Partnership purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth about $32,992,000. Balyasny Asset Management L.P. raised its position in shares of ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after purchasing an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth about $21,454,000. Rubric Capital Management LP raised its position in shares of ANI Pharmaceuticals by 354.7% in the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after purchasing an additional 200,998 shares during the last quarter. Finally, UBS Group AG raised its position in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Key Stories Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.